Univercells launches new vaccine manufacturing platform

By Sophie Bullimore | Published: 16-Jan-2019

Low-cost vaccine manufacturing technology, NevoLine, has been launched and already received grant for scale-up

A proprietary bioproduction system for vaccines is available on the market. Univercells is a biomanufacturing company that designed the new system, Nevoline, with resource support from Batavia Biosciences and Merck.

The first NevoLine system will be installed in Batavia Biosciences’ polio dedicated Biosafety level 3 Facility in Leiden, the Netherlands though it was developed by the Belgian-based Univercells.

NevoLine is an automated system that facilitates safer, faster and closed bioprocessing with a smaller footprint. Through intensification and chaining of unit steps into a continuous process, the process has high yields with less time and money invested.

Dr Pierre A Morgon, Non-Executive Director and Advisor to the CEO of Univercells, said: “Public health stands to gain handsomely from these new market dynamics, with biotherapeutics and vaccines being available in large enough volumes and at affordable prices.”

NevoLine, has been given a grant extension of US$4 million designated towards scaling up the original manufacturing platform. The extension follows the original $12m grant from the Bill and Melinda Gates Foundation to deliver affordable inactivated polio vaccine (sIPV).

The first NevoLine system is capable of a five-fold reduction in cost compared to current manufacturing technologies.

Hugues Bultot, Univercells CEO and co-founder, said: “This was a challenging two-year project aimed at delivering a new manufacturing system to drastically decrease cost, footprint and time to market for vaccine manufacturers, and we are pleased to have met these goals.”

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.

You may also like